NHLBI Will No Longer Participate in the Investigator-Initiated Innovative Research Grant (R21) Program
National Heart, Lung, and Blood Institute National Institutes of Health
July 22, 2011
The R21 grant mechanism is intended to encourage exploratory and developmental research by providing two years of support for the early and conceptual stages of research project development.
The R21 grant is meant to facilitate the award of larger regular research project grant (R01) applications by providing investigators with limited funds and time to pursue initial studies to obtain preliminary data for larger, more fully developed research projects. However, the NHLBI has determined that this grant mechanism is not having the effect or the impact on its research grant portfolio in the manner for which it was originally intended.
The NHLBI will no longer be a co-sponsor for the NIH R21 Parent Announcement, NIH Exploratory Developmental Research Grant Program. Consequently, the NHLBI will no longer accept investigator-initiated R21 applications in response to the NIH’s Parent Funding Opportunity Announcement (FOA). This new policy is described in NIH Guide Notice NOT-HL-11-154.
The NHLBI will not accept new unamended R21 applications in response to the Parent R21 FOA for the Cycle III due dates (October 16, 2011 or January 7, 2012 for AIDS applications) or any date thereafter. The NHLBI will accept resubmission (amended/A1) R21 applications through Cycle I, 2012 (March 16, 2012 or May 7, 2012 for AIDS applications). Starting with Cycle II, 2012 and thereafter, NHLBI will not accept any R21 applications in response to the NIH Exploratory Development Research Grant Program (Parent R21).
In the future, the NHLBI may issue highly targeted Funding Opportunity Announcements for R21 grant applications when scientific opportunities and needs arise that will benefit from the features and requirements of the R21 mechanism.
For general information and questions regarding the R21 program, individuals are encouraged to contact the appropriate scientific program Division within the NHLBI.
General Contact Information
Division of Cardiovascular Sciences
Dr. Michael Lauer Director NHLBI/DCVD Two Rockledge Center, Room 8124 6701 Rockledge Drive, MSC 7940 Bethesda, MD 20892-7940 Phone: 301-435-0466 Fax: 301-480-7971
Email:
nhlbi_dcvs@nhlbi.nih.gov
Division of Lung Diseases
Dr. James Kiley Director NHLBI/DLD Two Rockledge Center, Room 10042 6701 Rockledge Drive, MSC 7952 Bethesda, MD 20892-7952 Phone: 301-435-0233 Fax: 301-480-3547
Email:
nhlbi_dld@nhlbi.nih.gov
Division of Blood Diseases and Resources
Dr. W. Keith Hoots Director NHLBI/DBDR Two Rockledge Center, Room 9136 6701 Rockledge Drive, MSC 7950 Bethesda, MD 20892-7950 Phone: 301-435-0080 Fax: 301-480-0867 Email: hootswk@nhlbi.nih.gov
Last Updated July 2011 |